Experience in managing a patient with a complicated course of SARS-CoV-2 infection: early pulmonary rehabilitation and prevention of pulmonary fibrosis : clinical case

The article presents the clinical case of a complicated course of a new coronavirus infection - COVID-19 from the practice of a pulmonologis

Hyperuricemia as a risk factor for cardiovascular events in hypertensive patients

Hypertension (HTN) remains one of the most important risk factors for cardiovascular events. Modification of additional risk factors, along with a blood pressure decrease, significantly affects the risk of cardiovascular events. Hyperuricemia is one of the new factors that has a high prevalence in the population and affects the risk for cardiovascular events in hypertensive patients. In the treatment with fixed-dose combinations in patients with hypertension and hyperuricemia, metabolic neutrality is of particular importance. When prescribing diuretics, the practitioner faces additional difficulties. These drugs are highly synergistic when added to other major antihypertensives’ classes, but, in some cases, may worsen the metabolic profile. The use of the thiazide-like diuretic indapamide largely avoids a negative effect on the metabolic profile, making it the preferred choice for patients with hyperuricemia

Efficacy and tolerance of Arifam in patients with arterial hypertension over 55 years old: main results of the observational program ARBALET

Aim. To assess the effectiveness and safety of therapy with fixed combination of amlodipine/indapamide (Arifam) in outpatients with arterial hypertension (AH) over 55 years old.Material and methods. We included 2217 patients in the observation — 692 (31%) men and 1521 (69%) women. Changes in the course of 3-month therapy of systolic and diastolic blood pressure (BP), the frequency of achievement of target BP levels (<140/90 mm Hg), responder rate during the clinical and ambulatory blood pressure measurement were evaluated and.Results. With the use of Arifam fixed combination 89,81% of patients achieved target BP level by the 3rd month of treatment, 73,77% of patients achieved positive response in 2 weeks, 94,88% of patients — after 1 month. According to the selfcontrol data, the target BP level (<135/85 mm Hg) was achieved in 79,47% of patients. The number of patients with pulse BP <60 mm Hg increased after 3 months of treatment to 81,97%. Also 48 (2,17%) patients discontinued participation; 6 (0,28%) patients — due to the development of adverse events.Conclusion. The ARBALET program has demonstrated high efficacy and tolerance of using Arifam fixed combination in outpatients over 55 years old with hypertension

Efficacy and tolerance of Arifam in patients with arterial hypertension over 55 years old: Main results of the observational program ARBALET

Aim. To assess the effectiveness and safety of therapy with fixed combination of amlodipine/indapamide (Arifam) in outpatients with arterial hypertension (AH) over 55 years old. Material and methods. We included 2217 patients in the observation — 692 (31%) men and 1521 (69%) women. Changes in the course of 3-month therapy of systolic and diastolic blood pressure (BP), the frequency of achievement of target BP levels (<140/90 mm Hg), responder rate during the clinical and ambulatory blood pressure measurement were evaluated and. Results. With the use of Arifam fixed combination 89,81% of patients achieved target BP level by the 3rd month of treatment, 73,77% of patients achieved positive response in 2 weeks, 94,88% of patients — after 1 month. According to the selfcontrol data, the target BP level (<135/85 mm Hg) was achieved in 79,47% of patients. The number of patients with pulse BP <60 mm Hg increased after 3 months of treatment to 81,97%. Also 48 (2,17%) patients discontinued participation; 6 (0,28%) patients — due to the development of adverse events. Conclusion. The ARBALET program has demonstrated high efficacy and tolerance of using Arifam fixed combination in outpatients over 55 years old with hypertension. © 2018, Silicea-Poligraf. All rights reserved